Impact of comorbidities on patients with COVID‐19: A large retrospective study in Zhejiang, China

Abstract

Coronavirus disease 2019 (COVID-19) has become a serious public health problem worldwide. Here, we stratified COVID-19 patients based on their comorbidities to assess their risk of serious adverse outcomes. We collected 856 hospitalized cases diagnosed with COVID-19 from 17 January to 7 February 2020, in Zhejiang Province, and analyzed their comorbidities and composite endpoint (including admission to intensive care unit owing to disease progression, shock, invasive ventilation, and death) to determine the relationship between comorbidities and adverse outcomes. The median age of patients was 46 (36-56) years; 439 (51.3%) were men, 242 (28.3%) had comorbidities, and 152 (17.8%) had two or more comorbidities. The most common comorbidity was hypertension (142 [16.6%]), followed by diabetes (64 [7.5%]). Of the 856 patients, there are 154 (18.0%) severe cases. Thirty-two (3.7%) reached composite endpoints, of which 22 (9.1%) were from the comorbidity group and 10 (1.6%) from the non-comorbidity group (P < .001). After adjusting for age and gender status, the risk of reaching the composite endpoint was higher in the group with comorbidity than in that without comorbidity (hazard ratio [HR] 3.04, 95% confidence interval [CI]: 1.40-6.60). HR values for patients with one, two, and three or more comorbidities were 1.61 (95% CI: 0.44-5.91), 3.44 (95% CI: 1.31-9.08), and 6.90 (95% CI: 2.69-17.69), respectively. COVID-19 patients with comorbidities had worse clinical outcomes as compared with those without any comorbidity. The higher the number of comorbidities, the greater was the risk of serious adverse outcomes.

Characterization of Dental Surgeons of Pernambuco State in the COVID-19 Pandemic Context: Preliminary Data

“…This health condition can keep them away from work for fear of getting worse in case of contamination. The literature reports the association between the presence of comorbidities and the worsening of the outcomes of patients with the infection of the new coronavirus, in addition to pointing out that the increase in the number of these comorbidities increases the severity of the outcomes [14].…”

Impact of Chronic Use of Antimalarials on SARS-CoV-2 Infection in Patients With Immune-Mediated Rheumatic Diseases: Protocol for a Multicentric Observational Cohort Study

“…Considering a moderate-to-severe COVID-19 rate as the dependent variable, a rate which the current literature estimates to be 20% [ 4 , 6 , 10 - 18 , 40 - 42 ] as well as the proportion of 1 case for every 2 controls, the sample calculation was approximately 3000 antimalarial users and 6000 nonusers, with an error α=5% and β=20%.…”

“…Those infected with COVID-19 range from asymptomatic individuals to critically ill patients with outcomes like severe acute respiratory syndrome, coagulopathy (a prothrombotic state triggered by inflammation and other factors), and death [ 7 - 13 ]. Age and concomitant diseases, especially hypertension, diabetes, and heart, kidney, and lung diseases, are associated with poor outcomes [ 14 - 18 ].…”

Battle for supremacy: nucleic acid interactions between viruses and cells

“…The virus spreads mainly through respiratory droplets and causes a wide range of symptoms, from asymptomatic infection to severe disease with respiratory, renal and cardiac failure (3). Several studies of people in the United States and China infected with SARS-CoV-2 have reported risk factors for severity of disease including increased age, assignment of male gender at birth and comorbidities like obesity, hypertension and type 2 diabetes (4)(5)(6)(7)(8). Public Health England reported that people from black, Asian and minority ethnic groups had a higher risk of death from COVID-19 than people from a white British background.…”